{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:24:00Z","timestamp":1787664240814,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10147-026-03109-9","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:50:28Z","timestamp":1782859828000},"page":"1966-1974","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy, safety, and treatment feasibility of pembrolizumab plus lenvatinib in patients aged 75 years or older with advanced renal cell carcinoma: a Japanese multicenter retrospective study"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7402-6164","authenticated-orcid":false,"given":"Shimpei","family":"Yamashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Tomida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makito","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikko","family":"Tomisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Kohjimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"14","key":"3109_CR1","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R De Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Gr\u00fcnwald V, Hutson TE, Kopyltsov E, M\u00e9ndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK (2021) Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med 384(14):1289\u20131300. https:\/\/doi.org\/10.1056\/NEJMoa2035716","journal-title":"N Engl J Med"},{"issue":"11","key":"3109_CR2","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/jco.23.01569","volume":"42","author":"RJ De Motzer","year":"2024","unstructured":"Motzer RJ, Porta C, Eto M, Powles T, Gr\u00fcnwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, M\u00e9ndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK (2024) Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. J Clin Oncol 42(11):1222\u20131228. https:\/\/doi.org\/10.1200\/jco.23.01569","journal-title":"J Clin Oncol"},{"issue":"6","key":"3109_CR3","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/s1470-2045(18)30125-6","volume":"19","author":"R Le Kanesvaran","year":"2018","unstructured":"Kanesvaran R, Le Saux O, Motzer R, Choueiri TK, Scott\u00e9 F, Bellmunt J, Launay-Vacher V (2018) Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. Lancet Oncol 19(6):e317\u2013e326. https:\/\/doi.org\/10.1016\/s1470-2045(18)30125-6","journal-title":"Lancet Oncol"},{"issue":"26","key":"3109_CR4","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/jco.23.00933","volume":"41","author":"W Dale Jr.","year":"2023","unstructured":"Dale W, Klepin HD, Williams GR, Alibhai SMH, Bergerot C, Brintzenhofeszoc K, Hopkins JO, Jhawer MP, Katheria V, Loh KP, Lowenstein LM, McKoy JM, Noronha V, Phillips T, Rosko AE, Ruegg T, Schiaffino MK, Simmons JF Jr., Subbiah I, Tew WP, Webb TL, Whitehead M, Somerfield MR, Mohile SG (2023) Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update. J Clin Oncol 41(26):4293\u20134312. https:\/\/doi.org\/10.1200\/jco.23.00933","journal-title":"J Clin Oncol"},{"issue":"6","key":"3109_CR5","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00262-022-03341-y","volume":"72","author":"Y Fujiwara","year":"2023","unstructured":"Fujiwara Y, Miyashita H, Liaw BC (2023) First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis. Cancer Immunol Immunother 72(6):1355\u20131364. https:\/\/doi.org\/10.1007\/s00262-022-03341-y","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"3109_CR6","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/mou.0000000000000889","volume":"31","author":"F Quhal","year":"2021","unstructured":"Quhal F, Mori K, Remzi M, Fajkovic H, Shariat SF, Schmidinger M (2021) Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis. Curr Opin Urol 31(4):332\u2013339. https:\/\/doi.org\/10.1097\/mou.0000000000000889","journal-title":"Curr Opin Urol"},{"issue":"12","key":"3109_CR7","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s10147-024-02633-w","volume":"29","author":"T Hara","year":"2024","unstructured":"Hara T, Suzuki K, Okamura Y, Chiba K, Sato R, Matsushita Y, Tamura K, Ishikawa G, Otsuka A, Miyake H (2024) Efficacy and safety of lenvatinib and pembrolizumab as first-line treatment for advanced renal cell carcinoma patients: real-world experience in Japan. Int J Clin Oncol 29(12):1931\u20131936. https:\/\/doi.org\/10.1007\/s10147-024-02633-w","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"3109_CR8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00262-025-04019-x","volume":"74","author":"C De Porta","year":"2025","unstructured":"Porta C, Massari F, Taha T, Grande E, Bourlon MT, Kanesvaran R, Basso U, Molina-Cerrillo J, Alonso-Gordoa T, Myint ZW, Fornarini G, Buttner T, Park SH, \u00dcr\u00fcn Y, De Giorgi U, Pichler R, Rescigno P, Buchler T, Studentova H, Melichar B, Ansari J, Mollica V, Kucharz J, Rizzo M, Rizzo A, Kopp RM, Buti S, Monteiro FSM, Soares A, Bamias A, Santoni M (2025) Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study. Cancer Immunol Immunother 74(7):196. https:\/\/doi.org\/10.1007\/s00262-025-04019-x","journal-title":"Cancer Immunol Immunother"},{"key":"3109_CR9","doi-asserted-by":"publisher","first-page":"100142","DOI":"10.1016\/j.esmorw.2025.100142","volume":"8","author":"R Stelmach","year":"2025","unstructured":"Stelmach R, Erdmann S, Schlack K, Muehle C, Darr C, Neuberger S, Reichert M, Flegar L, Egenolf T, Rehlinghaus M, Zengerling F, Casuscelli J, Cox A, Vallet S, Nestler T, Brehmer B, Ivanyi P, Paffenholz P, Neuberger M, J\u00e4ger D, Gr\u00fcnwald V, Zsch\u00e4bitz S (2025) Effectiveness, toxicity and treatment adjustments of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: a multicenter real-world analysis. ESMO Real World Data Digit Oncol 8:100142. https:\/\/doi.org\/10.1016\/j.esmorw.2025.100142","journal-title":"ESMO Real World Data Digit Oncol"},{"issue":"1","key":"3109_CR10","doi-asserted-by":"publisher","first-page":"43676","DOI":"10.1038\/s41598-025-27578-6","volume":"15","author":"T Kato","year":"2025","unstructured":"Kato T, Nakai Y, Sato M, Takao T, Iwanishi T, Toyoda S, Osaki H, Tsujihata M, Okada K, Kakimoto K, Horitani H, Ono Y, Nishimura K, Takada S, Fujita K, Takayama H, Miyake O, Nakayama M, Ishizuya Y, Hayashi T, Yamamoto Y, Hatano K, Kawashima A, Nonomura N (2025) Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective study. Sci Rep 15(1):43676. https:\/\/doi.org\/10.1038\/s41598-025-27578-6","journal-title":"Sci Rep"},{"key":"3109_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030474","author":"S Yamashita","year":"2025","unstructured":"Yamashita S, Hamamoto S, Furukawa J, Fujita K, Takahashi M, Miyake M, Ito N, Iwamoto H, Kohjimoto Y, Hara I (2025) Efficacy and Safety of Nivolumab Plus Ipilimumab for Metastatic Renal Cell Carcinoma in Patients 75 Years and Older: Multicenter Retrospective Study. Cancers. https:\/\/doi.org\/10.3390\/cancers17030474","journal-title":"Cancers"},{"issue":"32","key":"3109_CR12","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1200\/jco.21.02017","volume":"40","author":"A Gilbert","year":"2022","unstructured":"Gilbert A, Piccinin C, Velikova G, Groenvold M, Kuli\u015b D, Blazeby JM, Bottomley A (2022) Linking the European Organisation for Research and Treatment of Cancer Item Library to the Common Terminology Criteria for Adverse Events. J Clin Oncol 40(32):3770\u20133780. https:\/\/doi.org\/10.1200\/jco.21.02017","journal-title":"J Clin Oncol"},{"issue":"2","key":"3109_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"11","key":"3109_CR14","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.21873\/anticanres.17333","volume":"44","author":"K Ueda","year":"2024","unstructured":"Ueda K, Ito N, Sakai Y, Ohnishi S, Hirano T, Kurose H, Chikui K, Uemura K, Nishihara K, Nakiri M, Suekane S, Igawa T (2024) Efficacy and Safety of Nivolumab With Ipilimumab in Elderly Patients With Advanced Renal Cell Carcinoma. Anticancer Res 44(11):5087\u20135093. https:\/\/doi.org\/10.21873\/anticanres.17333","journal-title":"Anticancer Res"},{"issue":"2","key":"3109_CR15","doi-asserted-by":"publisher","first-page":"100450","DOI":"10.1016\/j.esmoop.2022.100450","volume":"7","author":"Y Tomita","year":"2022","unstructured":"Tomita Y, Motzer RJ, Choueiri TK, Rini BI, Miyake H, Uemura H, Albiges L, Fujii Y, Umeyama Y, Wang J, Mariani M, Schmidinger M (2022) Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101. ESMO Open 7(2):100450. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100450","journal-title":"ESMO Open"},{"issue":"10","key":"3109_CR16","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1007\/s11255-025-04486-2","volume":"57","author":"Y Nemoto","year":"2025","unstructured":"Nemoto Y, Endo T, Segawa H, Nakamura K, Nishimura K, Horiuchi T, Toki D, Kobayashi H, Takagi T, Kondo T (2025) Efficacy and safety of nivolumab plus cabozantinib in octogenarian patients with advanced renal cell carcinoma. Int J Urol Nephrol 57(10):3191\u20133198. https:\/\/doi.org\/10.1007\/s11255-025-04486-2","journal-title":"Int J Urol Nephrol"},{"key":"3109_CR17","doi-asserted-by":"publisher","first-page":"1668406","DOI":"10.3389\/fimmu.2025.1668406","volume":"16","author":"H Ikoma","year":"2025","unstructured":"Ikoma H, Hamamoto S, Tasaki Y, Tomita M, Sakata T, Suzuki H, Noda Y, Usami M, Tsubouchi Y, Mimura Y, Morikawa T, Nagai T, Unno R, Etani T, Naiki T, Sugiyama Y, Yasui T (2025) Real-world outcomes of immune checkpoint inhibitor-based combination therapy in older adult patients with metastatic renal cell carcinoma: a multi-center, retrospective analysis. Front Immunol 16:1668406. https:\/\/doi.org\/10.3389\/fimmu.2025.1668406","journal-title":"Front Immunol"},{"issue":"11","key":"3109_CR18","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1093\/jjco\/hyaf122","volume":"55","author":"T Sazuka","year":"2025","unstructured":"Sazuka T, Murakami K, Nihei H, Iida Y, Mikami K, Pae S, Saito S, Ando K, Kanesaka M, Sato K, Yamada Y, Imamura Y, Sakamoto S, Ichikawa T (2025) Consecutive real-world treatment experience with a reduced starting dose of lenvatinib (14 mg) plus pembrolizumab for metastatic renal cell carcinoma. Jpn J Clin Oncol 55(11):1292\u20131296. https:\/\/doi.org\/10.1093\/jjco\/hyaf122","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"3109_CR19","doi-asserted-by":"publisher","first-page":"102153","DOI":"10.1016\/j.jgo.2024.102153","volume":"16","author":"G Aleixo","year":"2025","unstructured":"Aleixo G, Patel T, Ani J, Ferrell WJ, Dotan E, Takvorian SU, Williams GR, Parikh RB, Sedhom R (2025) Start low, go slow, a strategy to tailor treatment dosing in older or vulnerable adults with advanced solid cancer: A systematic review and meta-analysis. J Geriatr Oncol 16(2):102153. https:\/\/doi.org\/10.1016\/j.jgo.2024.102153","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"3109_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.eururo.2023.01.001","volume":"84","author":"MS Ernst","year":"2023","unstructured":"Ernst MS, Navani V, Wells JC, Donskov F, Basappa N, Labaki C, Pal SK, Meza L, Wood LA, Ernst DS, Szabados B, McKay RR, Parnis F, Suarez C, Yuasa T, Lalani AK, Alva A, Bjarnason GA, Choueiri TK, Heng DYC (2023) Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol 84(1):109\u2013116. https:\/\/doi.org\/10.1016\/j.eururo.2023.01.001","journal-title":"Eur Urol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03109-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03109-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03109-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:08:42Z","timestamp":1787663322000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03109-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3109"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03109-9","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"1 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Shimpei Yamashita reports honoraria\/fees from MSD and Eisai. Kosuke Ueda reports honoraria\/fees from MSD. Yasuo Kohjimoto reports honoraria\/fees from Astellas, and research funding from Mediscience Planning Mochida Pharmaceutical, ICON Clinical Research and MSD. Takeshi Yamasaki, Ryotaro Tomida, Shingo Toyoda, Hiroaki Iwamoto, Makito Miyake, Ikko Tomisaki, and Shuichi Morizane declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Wakayama Medical University Institutional Review Board (approval number 4612) and the ethics committees of all participating institutions. Patient consent for participation was obtained using the opt-out method or written informed consent.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Supplementary","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}]}}